Loading…

Apnimed, Inc.APMDCompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology
Mkt cap
$726M
US dollars, full cap
Free float
75%
of shares outstanding
$/day
$6.66M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 19.3%
Hurdle
n/a
no reverse DCF
Next earnings
105 days
3 Mar 2027
Close · USD$17.45
1D-2.0%
1W+4.0%
1M-5.7%
3M-38.9%
6Mn/a
YTDn/a
1Yn/a
ATR %9.5%
52w lowhigh50.5% off high

What Apnimed does

No business profile yet.

Apnimed at a glance

Size Apnimed (APMD) is a United States Health Care company (Biotechnology) with a market value of $726M, the 2434th largest of 3,085 United States companies the cockpit tracks. Shares closed at $17.45 on 18 Nov 2026.

Growth Revenue grew 380.1% over the last twelve months (peer median +7.1%); the operating margin is -139.9% (peer median -76.8%).

Valuation It trades at 10.8× enterprise value to sales against a peer median of 6.8× (8th most expensive of 17).

Short interest Short interest is 3.8% of the free float (30 Oct 2026).

Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).

Apnimed financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenuen/a$38.5M$8.01M$0$1.00M
Revenue growth—+380%—-100%—
Gross profitn/a$31.8M$4.64M-$1,000n/a
EBITDAn/a-$53.8M-$114M-$48.5M-$26.5M
Net incomen/a-$128M-$111M-$80.2M-$26.2M
Free cash flown/a-$77.8M-$110M$25.4M-$26.1M
Capital expendituren/a$0$70,000$47,000$0
Total debt$39.7M$41.5M$1.09M$0$109,000

Quarterly statements and history in the cockpit →

Apnimed competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Fundamentals: revenue growth against valuation

0%+2,000%+4,000%0×5,000×10,000×301333002038IVA688197MGTXAPMDRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Apnimed is the large dot.

Apnimed competitors and peer comparison

How Apnimed compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Apnimed against its 20 peers (data as of 18 Nov 2026)
MeasureAPMDPeer medianRank in peer set
1-month return-5.7%-7.2%9th highest of 21
Distance from 52-week high-50.5%-46.5%9th lowest of 21
Revenue growth (TTM)+380.1%+7.1%3rd highest of 15
Operating margin-139.9%-76.8%6th lowest of 17
EV / Sales10.8×6.8×8th most expensive of 17

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Apnimed APMDUnited States$726Mn/a+380%-140%10.8×n/an/a
R&G PharmaStudies 301333.SZChina$722M-11%+21%11%3.4×17.3%+11.8%
Beijing SL Pharmaceutical 002038.SZChina$736M-20%-4%-119%6.9×-13.5%-10.9%
Shaanxi Micot Pharmaceutical Technology 2335.HKHong Kong$715Mn/an/an/an/an/an/a
Aura Biosciences AURAUnited States$743M-4%n/an/an/an/an/a
Attovia Therapeutics ATTOUnited States$710M+1,325%n/a-5,945%220.7×n/an/a
Solid Biosciences SLDBUnited States$709M-2%n/an/an/an/an/a
Prime Medicine PRMEUnited States$695M+35%+18%-2,584%105.4×n/an/a
Inventiva IVA.PAFrance$763M-36%-100%-307,063%12,169.8×n/an/a
Nanjing Leads Biolabs 9887.HKHong Kong$764M-50%n/a-108%21.1×n/an/a
Syndax Pharmaceuticals SNDXUnited States$771M-57%+160%-62%3.2×n/an/a
Anhui Wanbang Pharmaceutical Technology 301520.SZChina$684M+74%-15%-8%14.7×44.8%+14.7%
Monte Rosa Therapeutics GLUEUnited States$775M-51%-61%-214%3.3×n/an/a
Wuhan Keqian Biology 688526.SSChina$780M-24%-22%20%4.4×7.8%+2.4%
Kura Oncology KURAUnited States$674M-29%-24%-394%2.6×n/an/a
Steminent Biotherapeutics 7729.TWOTaiwan$668M+292%n/an/an/an/an/a
Alphamab Oncology 9966.HKHong Kong$666M-38%-32%-38%6.7×n/an/a
Frontier Biotechnologies 688221.SSChina$658M-48%+153%-20%11.4×40.3%+21.5%
Shouyao Holdings Beijing 688197.SSChina$653M-26%+4,564%-92%38.1×n/an/a
MeiraGTx MGTXUnited States$813M-13%+1,366%44%1.9×n/an/a
Geron GERNUnited States$638M-21%+19%-8%2.8×n/an/a

Questions

Which companies are Apnimed's closest peers?
The cockpit's peer set: R&G PharmaStudies (301333.SZ), Beijing SL Pharmaceutical (002038.SZ), Shaanxi Micot Pharmaceutical Technology (2335.HK), Aura Biosciences (AURA), Attovia Therapeutics (ATTO), Solid Biosciences (SLDB), Prime Medicine (PRME), Inventiva (IVA.PA).
Is Apnimed expensive compared with its peers?
On ev / sales it trades at 10.8× against a peer median of 6.8×, 8th most expensive of 17 in its peer set.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.